^
    2years
    Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement-Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors. (PubMed, JTO Clin Res Rep)
    PC-9_v3a-gef and PC-9_v3b-gef cells were resistant to gefitinib and ALK inhibitors alone, but ALK inhibitors enhanced gefitinib-induced cytotoxicity. Furthermore, combination treatment with osimertinib and ceritinib caused a decrease in liver tumor size of the patient with liver metastases. Our data suggest that combination treatment with EGFR and ALK inhibitors can be a therapeutic strategy for treating NSCLC with concomitant EGFR mutation and EML4-ALK rearrangement.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • EML4 (EMAP Like 4)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ALK fusion • EML4-ALK variant 3 • EML4-ALK rearrangement • ALK V3a • ALK V3b • EML4-ALK variant 3a
    |
    Tagrisso (osimertinib) • gefitinib • Zykadia (ceritinib)
    3years
    Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged non-small cell lung cancer. (PubMed, J Thorac Oncol)
    Intratumoral EML4-ALK isoforms may predict the efficacy of targeted therapy in ALK-rearranged NSCLC. Temporal changes of intratumoral fusion isoforms may result from differential selection pressures that a drug might have on one isoform over another. Larger studies on fusion heterogeneity using RNA sequencing are warranted.
    Clinical • Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
    |
    ALK rearrangement • ALK fusion • ALK V3a • ALK V3b
    |
    Xalkori (crizotinib)